Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

By Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 375-382

Informa Healthcare

Access to resources Recommend Favorite

Darifenacin: a selective M₃ muscarinic receptor antagonist for the treatment of overactive bladder

By Smith Phillip P   Lai H Henry   Appell Rodney A  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 723-732

Future Medicine

Access to resources Recommend Favorite

Acupuncture versus Solifenacin for Treatment of Overactive Bladder and Its Correlation with Urine Nerve Growth Factor Levels: A Randomized, Placebo-Controlled Clinical Trial

By  

Urologia Internationalis, Vol. 93, Iss. 4, 2014-07 ,pp. : 437-443

Karger

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite